All insights
Markets

DCVC leads $62m Series B for stroke robotics firm Remedy ahead of approval trial

UC Investments and Australian pension fund Hostplus join as Remedy aims its AI-enabled N1 robot at FDA approval for neurovascular intervention.

By World Nexus Group Editorial

2 min read1 source

DCVC has led a $62 million Series B in Remedy Robotics, the San Francisco company building an AI-enabled robot to carry out endovascular procedures on site, from a distance or on its own, the company announced on 16 November 20261. The money is meant to take its N1 System through a planned approval trial with the University of California and on towards FDA approval for neurovascular intervention1.

The round and the plan

New investors are UC Investments, the University of California's investment office, together with Skip Capital and Hostplus, which Remedy describes as one of Australia's largest pension funds1. Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures, all existing backers, put in more1. The release does not give a valuation or the total Remedy has raised to date.

The N1 System uses machine learning to analyse imaging before a procedure, rehearse cases in simulation and register 3D and 2D images in real time, and is designed to complete whole endovascular procedures robotically1. Remedy says the round will also pay for prototype N1 Systems to go to clinical partners, among them SVIN Mission Thrombectomy and the Australian Stroke Alliance, and for work on autonomous functions1. Chief technology officer Jake Sganga said the plan includes "developing additional features including full autonomy"1.

Remedy says it works with more than 100 hospitals worldwide and holds 48 patents1. In October 2025 it reported the first remote neurointerventional procedures carried out with the N1 System1.

What it means for the market

The pitch to buyers is access rather than efficiency. Remedy puts the share of eligible stroke patients worldwide who can get endovascular treatment at 2.8 percent, because only specialists at a small number of hospitals can perform it1. A system that lets one specialist treat patients in other hospitals, or that works without one in the room, would change where stroke and heart attack services can be offered, and so how health systems plan and pay for them.

The investor list says something about who is backing that thesis. A deep-tech fund leads, the university that will host the approval trial invests through its own office, and an Australian pension fund joins alongside partnerships in Australia1. James Hardiman, general partner at DCVC, called Remedy part of "a new generation of medical robotics and physical AI companies"1. For competitors in vascular robotics and for imaging AI vendors, the combination of remote operation and stated ambitions for full autonomy sets a bar on the regulatory side as much as the technical one.

Caveats

The N1 System is still in development and is not available for sale or clinical use anywhere1. The approval trial is planned rather than under way, FDA approval is a goal rather than a filing, and the figures on disease burden and access are the company's own1. The next concrete step Remedy names is that trial, to be run across the University of California network1.

Sources

  1. 1Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere · PR Newswire

This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.